cmAngio® vs ElucidVivo A.3
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your primary objective is to non-invasively screen for early indicators of cardiovascular risk in women by analyzing existing mammograms. This tool is ideal for identifying Breast Arterial Calcifications (BAC) to flag patients who may benefit from further cardiovascular health evaluation, without requiring additional radiation or procedures.
View cmAngio® →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if you need advanced, quantitative analysis of arterial plaque composition and stability from CT angiography for patients with known or suspected atherosclerosis. This system is best suited for detailed patient stratification and optimizing treatment decisions by providing in-depth visualization and measurement of plaque characteristics, including Lipid-Rich Necrotic Core and derived FFRct.
View ElucidVivo A.3 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | ElucidVivo A.3 |
|---|---|---|
| Pricing | Paid, out-of-pocket | Unknown |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Cloud and on-premise secure deployment. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®Tool A explicitly highlights 'Quick and easy installation (less than an hour)' and 'Compatible with any DICOM-compliant viewer,' suggesting a streamlined integration into existing clinical workflows. Tool B's description focuses more on advanced visualization features rather than ease of initial setup or broad compatibility.
Clinical Value
ElucidVivo A.3While both are FDA-cleared and offer significant clinical value, Tool B provides a more in-depth, quantitative analysis of arterial plaque composition and stability, validated against histology, and derives fractional flow reserve (FFRct). This level of detail and validation offers a more comprehensive diagnostic and prognostic tool for atherosclerosis management, directly impacting treatment decisions. Tool A provides valuable early risk assessment from existing mammograms, but Tool B's offering is more granular and directly actionable for advanced disease.
Pricing & Value
cmAngio®Both tools require direct contact for pricing, indicating a lack of public transparency. However, Tool A explicitly mentions 'Limited-time offers for no-cost implementation and service may be available,' which could present a more attractive initial value proposition or lower barrier to entry compared to Tool B, which makes no such public offer.
Enterprise Readiness
cmAngio®Tool A explicitly states it is 'Cybersecure and HIPAA-compliant' and directs users to contact the vendor for Business Associate Agreement (BAA) details. While Tool B implies HIPAA compliance due to its FDA clearance and intended use in healthcare, it does not explicitly state these compliance details or mention BAAs in the provided facts, giving Tool A a slight edge in explicit enterprise assurance.
Innovation
ElucidVivo A.3Tool A innovates by extracting new cardiovascular risk insights (BAC) from existing mammography data. Tool B, however, demonstrates a higher degree of innovation through its AI-powered quantitative analysis of arterial plaque composition and stability, validated against ground-truth histology, and its ability to derive fractional flow reserve (FFRct). This represents a more advanced and multi-faceted application of AI in detailed cardiovascular diagnostics.
Support & Docs
TieNeither the provided structured facts nor available public information from web searches offer specific details regarding support channels, service level agreements, or publicly accessible documentation for either tool. Therefore, it is not possible to distinguish between them on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | ElucidVivo A.3 |
|---|---|---|
| Primary Function | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | FDA-cleared AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography. It assists physicians in atherosclerosis patient stratification and optimizes treatment decisions. |
| Input Imaging Modality | Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams | CT angiography |
| Analyzed Condition/Target | Breast Arterial Calcifications (BAC) for cardiovascular health risk assessment | Arterial plaque composition and stability for atherosclerosis patient stratification |
| Specific Analysis Capability | AI-based detection of Breast Arterial Calcifications (BAC) | AI-powered quantitative analysis of arterial plaque; objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images; derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity. |
| Visualization Feature | Provides visualization of BAC location on a scorecard | Visualizes lesion-level plaque composition; provides 3D visualization of highlighted vessels; offers rotatable curved MPR vessel views and cross-sections. |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and ElucidVivo A.3.